- Workshop presentation
- Open Access
Single breath-hold 3D mapping of T1 and T2 relaxation times with 3D-QALAS - feasibility in patients
© Kvernby et al; licensee BioMed Central Ltd. 2015
- Published: 3 February 2015
- Dilate Cardiomyopathy
- Breath Hold
- Idiopathic Dilate Cardiomyopathy
- Poor Renal Function
- Relaxation Time Measurement
A novel method for 3D interleaved T1 and T2 mapping of the whole left ventricular myocardium within one breath hold, 3D-QALAS, has recently been developed . The method has been evaluated both in phantoms and in healthy volunteers showing a good correlation to reference relaxation time mapping methods. The aim of this work was to investigate the feasibility of the method in patients with different cardiac pathologies and to extend the tested range of myocardial relaxation times by including measurements post injection of gadolinium (Gd) based contrast agents.
In this feasibility study, eleven patients from an ongoing study were consecutively included (clinically significant aortic stenosis, ischemic cardiomyopathy and idiopathic dilated cardiomyopathy). The 3D-QALAS sequence which measures T1 and T2 relaxation times in 13 slices with a resolution of 2mm x 2mm x 6mm was run twice on a Philips Ingenia 3T scanner both pre and post Gd in all patients except for one patient were only native data was collected, due to poor renal function. For comparison, three (apical, mid-ventricular and basal) 2D 3-3-5 MOLLI acquisitions  were performed for myocardial T1 mapping pre- and post-contrast and three 2D multi-echo GraSE acquisitions were performed for T2 mapping pre-contrast. Ten healthy volunteers underwent the same acquisitions pre contrast as the patients.
The preliminary results from this ongoing study indicate that 3D T1 and T2 mapping in the left ventricle is feasible in one breath hold for patients with different pathologies using 3D QALAS. The method shows a good correlation in relaxation times measurement with existing 2D T1 and T2 mapping methods.
Partly funded by the Swedish Heart and Lung Foundation.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.